Group 1 - The core viewpoint of the article is that Hubei Hongyuan Pharmaceutical Technology Co., Ltd. has received approval from its supervisory board to implement the 2025 Restricted Stock Incentive Plan, confirming that the company meets all necessary legal and regulatory requirements for such a plan [2][5]. - The company does not have any disqualifying conditions as outlined in the Management Measures for Stock Incentives, such as negative audit opinions or violations of profit distribution regulations [2][3]. - The proposed incentive plan excludes independent directors, shareholders holding 5% or more of the company's shares, and their immediate family members, ensuring compliance with relevant laws and regulations [3][4]. Group 2 - The incentive plan's design and review process adhere to the Company Law, Securities Law, and other applicable regulations, ensuring that the granting and vesting arrangements for restricted stocks do not violate any laws or harm the interests of the company and its shareholders [3][4]. - The company will publicly disclose the names and positions of the incentive plan participants for at least 10 days before the shareholders' meeting, ensuring transparency in the process [3]. - The implementation of the stock incentive plan is expected to enhance the company's incentive mechanism, align the interests of management and shareholders, and contribute to the company's sustainable development [4][5].
宏源药业: 监事会关于公司2025年限制性股票激励计划相关事项的核查意见